Concert Pharma - About the company
Concert Pharma is an acquired company based in Lexington (United States), founded in 2006. It operates as a Developer of multiple drug candidates to treat multiple diseases. Concert Pharma has raised $85.5M in funding, with last known valuation of $*****. The company has 4011 active competitors, including 1326 funded and 888 that have exited. Its top competitors include companies like BeiGene, Jazz Pharmaceuticals and Kite Pharma.
Company Details
Developer of multiple drug candidates to treat multiple diseases. The company's lead product candidate is CTP-543 for the treatment of alopecia areata, a serious autoimmune dermatological condition.
- Website
- concertpharma.com
- Registered Address
- Lexington, Massachusetts
Key Metrics
Founded Year
2006
Location
Lexington, United States
Stage
Acquired
Total Funding
$85.5M in 3 rounds
Latest Funding Round
Last Known Valuation
$***** as on Jan 19, 2023
Investors
Ranked
930th among 4011 active competitors
Employee Count
50 - 199 as on Mar 01, 2026
Exit Details
Acquired by Sun Pharma (Jan 19, 2023)
Legal entities associated with Concert Pharma
Concert Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CONCERT PHARMACEUTICALS, INC. CIN: 204839882 , United States, Active | Dec 26, 999 | - | 67 (As on Dec 31, 2022) | - |
Concert Pharma's acquisition details
Concert Pharma got acquired by Sun Pharma on Jan 19, 2023 at an acquisition amount of $*****.
Click here to take a look at Concert Pharma's acquisition in detail
Sign up to download Concert Pharma's company profile
Concert Pharma's funding and investors
Concert Pharma has raised a total funding of $85.5M over 3 rounds. Its first funding round was on Nov 30, 2006. Its latest funding round was a Post IPO round on Nov 04, 2021 for $*****. 2 investors participated in its latest round. Concert Pharma has 17 institutional investors.
Here is the list of recent funding rounds of Concert Pharma:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Nov 04, 2021 | 6507252 | Post IPO | 2009501 | 7276422 | 6187734 | 3177409 |
Apr 30, 2008 | 2922055 | Series C | 3897762 | 4459540 | 7444064 | |
Nov 30, 2006 | 5975398 | Series B | 1606473 | 3933522 | 3252453 |
Access funding benchmarks and valuations. Sign up today!View details of Concert Pharma's funding rounds and investors
Concert Pharma's founders and board of directors
Founder? Claim ProfileConcert Pharma's employee count trend
Concert Pharma has 50 - 199 employees as of Mar 26. Here is Concert Pharma's employee count trend over the years:
Uncover Concert Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Concert Pharma's Competitors and alternates
Top competitors of Concert Pharma include BeiGene, Jazz Pharmaceuticals and Kite Pharma. Here is the list of Top 10 competitors of Concert Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
2nd |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
3rd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 76/100 | |
4th | Denali Therapeutics 2015, San Francisco (United States), Public | Developer of therapies to treat neurodegenerative diseases | $347M | 74/100 | |
5th |  Attovia 2023, Fremont (United States), Public | Developer of antibody-based therapeutics for immune-mediated diseases and oncology | $255M | 72/100 | |
6th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 72/100 | |
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
930th | Concert Pharma 2006, Lexington (United States), Acquired | Developer of multiple drug candidates to treat multiple diseases | $85.5M | 44/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Concert Pharma's competitors? Click here to see the top ones
Concert Pharma's Investments and acquisitions
Concert Pharma has made no investments or acquisitions yet.
Reports related to Concert Pharma
Here is the latest report on Concert Pharma's sector:
News related to Concert Pharma
Filter this list•
Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia AreataPipelinereview•Mar 19, 2023•Concert Pharma, Sun Pharma
•
Sun Pharma completes acquisition of US-based Concert PharmaceuticalsBusiness Standard•Mar 06, 2023•Sun Pharma, Concert Pharma
•
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia AreataBusiness Wire•Feb 15, 2023•Concert Pharma
•
Halper Sadeh LLC Is Investigating Whether the Sale of Concert Pharmaceuticals, Inc. Is Fair to ShareholdersBusiness Wire•Feb 13, 2023•Halper Sadeh, Concert Pharma, Sun Pharma
•
Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing InvestigationsPR Newswire•Feb 07, 2023•Weisslawllp, Evoqua, Leap Therapeutics, Concert Pharma and 1 other
•
Halper Sadeh LLC Investigates CNCE, AQUA, LPTX, ALRPR Newswire•Feb 07, 2023•Halper Sadeh, Concert Pharma, Evoqua, Leap Therapeutics and 1 other
•
The M&A Class Action Firm Continues Investigating the Merger – ANGN, CNCE, VLONGlobeNewswire•Jan 21, 2023•Monteverde, Angion Biomedica, Elicio, Concert Pharma and 3 others
•
•
Weiss Law Investigates Concert Pharmaceuticals, Inc.PR Newswire•Jan 20, 2023•Weisslawllp, Concert Pharma
•
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia AreataTullahoma News•Jan 19, 2023•Sun Pharma, Concert Pharma, Davis Polk
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Concert Pharma
Explore our recently published companies
- LifeLine Medical Devices - Gurugram based, 1986 founded, Unfunded company
- Seededge Solutions - Pune based, Unfunded company
- Secuarden AI - Melbourne based, 2026 founded, Unfunded company
- Secretair AI - France based, 2025 founded, Unfunded company
- Second Loop AI - Unfunded company
- Seawin AI - Unfunded company
